Understanding decentralised clinical trials

Understanding Decentralized Clinical Trials

Decentralized clinical trials represent a major transformation in modern research. This innovative approach allows patients to take part in clinical studies from home through new technologies. It revolutionizes access to clinical trials by removing traditional geographic and time constraints while maintaining strict compliance with the regulatory framework set by health authorities.

What Is a Decentralized Clinical Trial?

Decentralized clinical trials are defined by their ability to move part or all of the research activities outside traditional hospital centers. This model relies on technological tools that enable data collection directly from participants’ homes.

Main advantages:

• Reduced logistical constraints for participants
  
  
• Easier access for rural or mobility-limited populations
  
  
• Lower operational costs
  
  
• Improved patient recruitment and retention
  
  
• Real-world data collection
  
  

This evolution fundamentally changes the relationship between researchers and participants. Patients become more autonomous actors, using mobile applications to report symptoms or connected devices to transmit physiological data.

Regulatory Framework and Compliance

In France, implementing decentralized clinical trials requires strict compliance with several regulatory texts. Health and data protection authorities impose particularly demanding guidelines regarding the collection of personal health data.

Key requirements:

• Adapted informed consent: Clear information on the technologies used and on how data are collected remotely
  
  
• Enhanced traceability: Documentation of all digital interactions with participants
  
  
• Data security: Encrypted transmissions and secured databases
  
  We describe how we protect trial data on our security page.

Healthcare professionals must also ensure that participants fully understand the implications of their participation in a partly remote clinical trial, thereby upholding research ethics.

What does the French law of 26 May 2026 change for at-home research?

Since 28 May 2026, the patient's home is one of the places where research can take place in France. Law No. 2026-403 of 26 May 2026 on simplifying economic life added it to Article L. 1121-13 of the French Public Health Code, together with "another nearby location required for the person's pathway in the research". The first administration of a medicinal product to humans remains restricted to authorized sites.

The rule covers research involving human participants and, through Article L. 1124-1, clinical trials of medicinal products under Regulation (EU) No 536/2014. Articles L. 1125-12 and L. 1126-11 apply it to clinical investigations of medical devices and to performance studies of in vitro diagnostic medical devices. Like any research site, the home must have human, material and technical resources suited to the research and compatible with participant safety. A category 1 interventional study that requires procedures there other than those usually performed in that place also needs an authorization from the director general of the regional health agency (ARS).

The law does not exempt the protocol from any review: the ethics committee (CPP) and, where it has jurisdiction, the French medicines agency (ANSM) assess a protocol with home visits like any other protocol. Four measures of the law concern research carried out outside the investigator site.

Article 54 also refers to Conseil d'État decrees for the CNIL reference frameworks and for an exemption from the opinion of the CESREES, limited to research not involving human participants. These decrees had not been published as of October 2026. The first three measures in the table do not depend on them and have applied since 28 May 2026.

For a trial run in France, the law adds to a European text. Annex 2 of ICH E6(R3), which takes effect in the EU on 15 January 2027, sets Good Clinical Practice rules for the decentralized elements of a trial, including activities at the participant's home. Our article on Annex 2 of ICH E6(R3) explains what it expects from the protocol and from remote consent.

If you plan home dispensing by the hospital pharmacy, write it into the protocol: Article L. 5126-7 makes it a condition. Also describe who visits the home and which procedures that person performs there, so the CPP can assess whether the location has the right resources.

Technologies Powering Decentralization

The technological ecosystem of decentralized trials is structured around three complementary pillars that are revolutionizing clinical data collection.

Teleconsultation Platforms

These tools allow investigators to maintain direct contact with patients, enabling medical consultations, clinical assessments, and therapeutic follow-ups without geographical constraints.

Dedicated Monitoring Platforms

• Interactive quality-of-life questionnaires
  
  
• Daily symptom diaries
  
  
• Treatment reminders
  
  
• Communication interfaces with the research team
  
  
• Educational modules about the studied pathology
  
  

Remote Monitoring Devices

Connected sensors are at the heart of this innovation: smart blood pressure monitors, connected scales, pulse oximeters, glucose monitors, and physical activity trackers. These devices automatically transmit data to the study databases, reducing entry errors while increasing the frequency and precision of measurements.

Integrating these technologies requires specific expertise in cybersecurity and system interoperability. Clinical research teams must master these new tools to ensure the reliability of collected data.

Toward a New Era of Medical Research

Decentralized clinical trials mark a decisive step in the evolution of medical research. This approach democratizes access to therapeutic innovation, particularly benefiting patients who live far from major hospital centers. It meets the expectations of today’s participants, who are accustomed to digital services and wish to balance care with daily life, while maintaining the high scientific standards essential to modern clinical research.

[[faq]]

Sources

• Légifrance, LOI n° 2026-403 du 26 mai 2026 de simplification de la vie économique, Articles 54, 56 and 57, JORF No. 0122 of 27 May 2026.
• Légifrance, Code de la santé publique, article L1121-13, version in force since 28 May 2026.
• Légifrance, Code de la santé publique, article L5126-7, version in force since 28 May 2026.
• Vie publique, Échéancier de la loi n° 2026-403 du 26 mai 2026, 2026.